$ARGS The ESMO presentation went well and the study suggests survivability with MRCC. I anticipate this is what Dr. Figlin is going to cover. https://www.esmo.org/Conferences/ESMO-2017-Congress/News-Articles/Rocapuldencel-T-Shows-Potential-Benefit-in-Metastatic-Renal-Cell-Carcinoma